Sakar Healthcare Ltd
Sakar Healthcare Q2 Results 2026 (FY27) statement: Revenue & Margins
Q2 FY27 results statement: what the company reported on revenue and margins.
Sakar Healthcare Ltd Q2 FY27 key numbers
- Revenue
- Revenue from operations for the quarter ended 30th September 2026: Rs. 8,741.61 lakh.
As stated in Sakar Healthcare Ltd's Q2 FY27 results statement · published 23 Oct 2026. Reported figures, not investment advice.
Based on Sakar Healthcare Ltd's Q2 FY27 results statement. The company has not published an earnings-call transcript for this quarter, so figures here are what the results statement reports, not management guidance.
The short version
Revenue from operations for the quarter ended 30th September 2026: Rs. Quarter ended 30 Sept 2026 (Q2 FY27) Financials: - EBITDA (Profit before exceptional items & tax + Depreciation & Finance costs): - Profit before tax and exceptional items: ₹1,602.04 lakh - Add: Depreciation ₹660.22 lakh + Finance costs ₹200.40 lakh - EBITDA = ₹1,602.04 + ₹660.22 + ₹200.40 = ₹2,462.66 lakh - Operating Margin (EBITDA margin): - Revenue from operations: ₹8,741.61 lakh - EBITDA Margin = (₹2,462.66 / ₹8,741.61) × 100 ≈ 28.17% - Profit After Tax (PAT): - ₹1,130.69 lakh for Q2 FY27 (compared to ₹453.98 lakh in Q2 FY26) - Year-on-Year growth in PAT: ((1,130.69 - 453.98) / 453.98) × 100 ≈ 148.9% - Explicit Margin Outlook: - The presentation does not explicitly state any margin outlook or guidance.
From Sakar Healthcare Ltd's Q2 FY27 earnings-call transcript · updated 23 Oct 2026.
Revenue & Sales Performance
Profitability & Margins
- Quarter ended 30 Sept 2026 (Q2 FY27) Financials:
- EBITDA (Profit before exceptional items & tax + Depreciation & Finance costs):
- Profit before tax and exceptional items: ₹1,602.04 lakh
- Add: Depreciation ₹660.22 lakh + Finance costs ₹200.40 lakh
- EBITDA = ₹1,602.04 + ₹660.22 + ₹200.40 = ₹2,462.66 lakh
- Operating Margin (EBITDA margin):
- Revenue from operations: ₹8,741.61 lakh
- EBITDA Margin = (₹2,462.66 / ₹8,741.61) × 100 ≈ 28.17%
- Profit After Tax (PAT):
- ₹1,130.69 lakh for Q2 FY27 (compared to ₹453.98 lakh in Q2 FY26)
- Year-on-Year growth in PAT: ((1,130.69 - 453.98) / 453.98) × 100 ≈ 148.9%
2 more points from Sakar Healthcare Ltd's call on margins
Pro opens every point from 15K+ earnings calls
Sakar Healthcare Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹87 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sakar Healthcare Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Torrent Pharmaceuticals Ltd (Q2 FY27)
4,979 crores, up 51% YoY (Page 23). Key results statement takeaways from Torrent Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sect
- Dr Reddys Laboratories Ltd (Q2 FY27)
Reported Q2FY27 revenues: ₹8,671 Cr, up 1.5% YoY and 7% QoQ (Page 4). Key investor presentation takeaways from Dr Reddys Laboratories Ltd's Q2 FY27 investor pre
- Beta Drugs Ltd (Q2 FY27)
H1 FY25: ₹180 Crs . Key investor presentation takeaways from Beta Drugs Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
- Bajaj Healthcare Ltd (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
Arthneeti Pro · Annual
Sakar Healthcare Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sakar Healthcare Ltd Q2 FY27 results?
Revenue from operations for the quarter ended 30th September 2026: Rs. Quarter ended 30 Sept 2026 (Q2 FY27) Financials: - EBITDA (Profit before exceptional items & tax + Depreciation & Finance costs): - Profit before tax and exceptional items: ₹1,602.04 lakh - Add: Depreciation ₹660.22 lakh + Finance costs ₹200.40 lakh - EBITDA = ₹1,602.04 + ₹660.22 + ₹200.40 = ₹2,462.66 lakh - Operating Margin (EBITDA margin): - Revenue from operations: ₹8,741.61 lakh - EBITDA Margin = (₹2,462.66 / ₹8,741.61) × 100 ≈ 28.17% - Profit After Tax (PAT): - ₹1,130.69 lakh for Q2 FY27 (compared to ₹453.98 lakh in Q2 FY26) - Year-on-Year growth in PAT: ((1,130.69 - 453.98) / 453.98) × 100 ≈ 148.9% - Explicit Margin Outlook: - The presentation does not explicitly state any margin outlook or guidance.
What is Sakar Healthcare Ltd share price analysis?
Sakar Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 54.9 with a market cap of ₹1,979 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sakar Healthcare Ltd planning capital expenditure?
The presentation does not explicitly describe any capital expenditure (capex), capacity expansion, or new plant/project details including amounts, status, or timelines.
Keep Sakar Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's results statement. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.